p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis
- PMID: 16651418
- DOI: 10.1158/0008-5472.CAN-05-2909
p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis
Abstract
To investigate the mechanisms through which p130Cas adaptor protein is linked to tumorigenesis, we generated mouse mammary tumor virus (MMTV)-p130Cas mice overexpressing p130Cas in the mammary gland. MMTVp130Cas transgenic mice are characterized by extensive mammary epithelial hyperplasia during development and pregnancy and by delayed involution at the end of lactation. These phenotypes are associated with activation of Src kinase, extracellular signal-regulated kinase 1/2, mitogen-activated protein kinase, and Akt pathways, leading to an increased rate of proliferation and a decreased apoptosis. A double-transgenic line derived from crossing MMTV-p130Cas with MMTV-HER2-Neu mice expressing the activated form of the HER2-Neu oncogene develops multifocal mammary tumors with a significantly shorter latency than the HER2-Neu parental strain alone. Mammary epithelial cells isolated from tumors of double-transgenic mice display increased tyrosine phosphorylation, c-Src, and Akt activation compared with cells derived from HER2-Neu tumors. In addition, p130Cas down-regulation by RNA interference increases apoptosis in HER2-Neu-expressing cells, indicating that p130Cas regulates cell survival. Consistently with the double-transgenic mice model, p130Cas is overexpressed in a significant subset of human breast cancers and high levels of p130Cas in association with HER2 expression correlate with elevated proliferation. These findings provide evidences for a role of p130Cas as a positive regulator of both proliferation and survival in normal and transformed mammary epithelial cells. Its overexpression contributes to HER2-Neu-induced breast tumorigenesis, thus identifying this protein as a putative target for clinical therapy.
Similar articles
-
Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.Int J Oncol. 2009 Feb;34(2):517-28. Int J Oncol. 2009. PMID: 19148488
-
Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.Cancer Res. 2007 Sep 15;67(18):8671-81. doi: 10.1158/0008-5472.CAN-07-1486. Cancer Res. 2007. PMID: 17875707
-
Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.Mol Cell Biol. 2007 Sep;27(18):6361-71. doi: 10.1128/MCB.00686-07. Epub 2007 Jul 16. Mol Cell Biol. 2007. PMID: 17636013 Free PMC article.
-
Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.Biochem Soc Symp. 1998;63:159-65. Biochem Soc Symp. 1998. PMID: 9513720 Review.
-
WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.Oncogene. 2000 Feb 21;19(8):1010-9. doi: 10.1038/sj.onc.1203271. Oncogene. 2000. PMID: 10713684 Review.
Cited by
-
Cas proteins: dodgy scaffolding in breast cancer.Breast Cancer Res. 2014;16(5):443. doi: 10.1186/s13058-014-0443-5. Breast Cancer Res. 2014. PMID: 25606587 Free PMC article. Review.
-
The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries.Nat Commun. 2017 Mar 16;8:14797. doi: 10.1038/ncomms14797. Nat Commun. 2017. PMID: 28300085 Free PMC article.
-
Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton.Genes Cancer. 2012 May;3(5-6):371-81. doi: 10.1177/1947601912458585. Genes Cancer. 2012. PMID: 23226575 Free PMC article.
-
Models of crk adaptor proteins in cancer.Genes Cancer. 2012 May;3(5-6):341-52. doi: 10.1177/1947601912459951. Genes Cancer. 2012. PMID: 23226572 Free PMC article.
-
Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.Oncogene. 2014 May 8;33(19):2441-53. doi: 10.1038/onc.2013.220. Epub 2013 Jun 17. Oncogene. 2014. Retraction in: Oncogene. 2024 Mar;43(14):1076. doi: 10.1038/s41388-024-02964-y. PMID: 23770848 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous